ArticleAIMS public health2020
Carbapenem-resistant
Article in AIMS public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Comprehensive genotypic report of carbapenem-resistant Klebsiella pneumoniae (CRKP) harboring carbapenemase-resistant genes, porin loss and efflux pump genes in Osun State, Nigeria.Molecular biology reports · 2025Article
- Characterization of Carbapenem-Resistant Gram-Negative Bacilli Isolates in Multispecialty Private Hospitals in Lagos, Nigeria.Infectious disease reports · 2025Article
- Improved diagnostic stewardship in carbapenem-resistantJournal of medical microbiology · 2025Article
- The magnitude of MDR carbapenemase-producing Enterobacteriaceae isolates and associated factors among hospitalized patients of Northeast Ethiopia.JAC-antimicrobial resistance · 2025Article
- Molecular Analysis of Tigecycline Resistance in Carbapenem-Resistant Enterobacterales (CRE) in Mthatha and Surrounding Hospitals.Antibiotics (Basel, Switzerland) · 2025Article
- Unveiling the impact: COVID-19's influence on bacterial resistance in the Kingdom of Bahrain.World journal of virology · 2025Article
- High prevalence of carbapenem-resistantHeliyon · 2024Article
- Potential of Selected African Medicinal Plants as Alternative Therapeutics against Multi-Drug-Resistant Bacteria.Biomedicines · 2023Review
- Individualized active surveillance for carbapenem-resistant microorganisms using Xpert Carba-R in intensive care units.Scientific reports · 2023Article
- Estimation, Evaluation and Characterization of Carbapenem Resistance Burden from a Tertiary Care Hospital, Pakistan.Antibiotics (Basel, Switzerland) · 2023Article
- Prevalence of carbapenem-resistant and extended-spectrum beta-lactamase-producing Enterobacteriaceae in a teaching hospital in Ghana.PloS one · 2023Article
- The Predominance ofPathogens (Basel, Switzerland) · 2022Article
- The Emergence ofAntibiotics (Basel, Switzerland) · 2021Article
- Phenotypic Detection of Carbapenem-Resistant Gram-Negative Bacilli from a Clinical Specimen in Sidama, Ethiopia: A Cross-Sectional Study.Infection and drug resistance · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenem-resistant
objectivesThe objective of this study was to investigate and describe the epidemiology of carbapenem-resistant
methodsA retrospective collection of microbiological laboratory records from the January to June 2018 was performed. All culture and antimicrobial susceptibility test results of patients who required laboratory tests were collected. Other information collected include: patient demographics, clinical specimen types and the requesting hospital department. The data was analyzed using SPSS Windows version 24. Comparison between categorical variables was done using chi-square tests while independent sample t-test was used to determine significant mean differences between groups. A
resultsThe prevalence of carbapenem-resistance among
conclusionCarbapenem resistance is an important threat to the current antibiotic armory. Active surveillance, particularly in the healthcare setting is required to identify high risk groups, inform better treatment options and infection prevention and control measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.